PTH - ETF AI Analysis
Top Page
Invesco DWA Healthcare Momentum ETF (PTH)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year and over the past few months, showing positive momentum.
High-Momentum Top Holdings
Several of the largest positions, especially in biotech and pharmaceuticals, have shown strong year-to-date performance, helping drive the fund’s returns.
Focused Healthcare Exposure
The fund’s near-total focus on the healthcare sector allows investors to target a specific area of the market that can benefit from medical innovation and long-term demand for health services.
Negative Factors
Single-Sector Concentration
With almost all assets in healthcare, the ETF is heavily exposed to downturns or policy changes that hurt this one sector.
Limited Geographic Diversification
The fund invests almost entirely in U.S. companies, offering little protection if the U.S. market or healthcare industry faces challenges.
Above-Average Expense Ratio
The ETF’s fee is relatively high compared with many broad index funds, which can eat into long-term returns.
PTH vs. SPDR S&P 500 ETF (SPY)
AUM114.84M
RegionNorth America
Expense Ratio0.60%
Beta1.00
IssuerInvesco
Inception DateOct 12, 2006
Dividend Yield3.15%
Asset ClassEquity
Index TrackedDorsey Wright Healthcare Tech Leaders TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,680
30 Day Avg. Volume9,128
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
74.39Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering58
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PTH Summary
The Invesco DWA Healthcare Momentum ETF (PTH) tracks the Dorsey Wright Healthcare Tech Leaders Index, focusing on U.S. healthcare companies that have been recently strong performers. It holds a mix of biotech, drug makers, medical device firms, and hospital operators, including well-known names like HCA Healthcare and Tenet Healthcare. Someone might invest in PTH to seek growth from medical innovation and rising healthcare demand, while spreading risk across many companies instead of picking single stocks. However, this fund is heavily focused on healthcare and momentum stocks, so its price can swing sharply and may fall quickly if the sector or trend weakens.
How much will it cost me?The Invesco DWA Healthcare Momentum ETF (Ticker: PTH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on momentum-driven strategies within the healthcare sector.
What would affect this ETF?The Invesco DWA Healthcare Momentum ETF (PTH) could benefit from ongoing advancements in healthcare technology, an aging population driving demand for medical services, and increased investment in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the healthcare industry, and potential economic downturns that could reduce consumer spending on healthcare. Its focus on U.S.-based healthcare companies and momentum-driven strategy makes it sensitive to market volatility and sector-specific trends.
PTH Top 10 Holdings
PTH is a pure-play U.S. healthcare momentum fund, and its story is being written mostly by fast-moving biotech names. Rising stocks like Roivant Sciences, Axsome Therapeutics, and Celcuity are giving the ETF a healthy pulse, as investors reward promising pipelines and upbeat news flow. Tango Therapeutics has been a rocket over the past few months, though its recent pullback shows how bumpy early-stage biotech can be. On the flip side, hospital operators like Tenet and HCA are losing steam, acting as a brake on performance in an otherwise growth-heavy portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Roivant Sciences | 4.97% | $5.55M | $20.56B | 154.50% | 58 Neutral | |
| Praxis Precision Medicines | 4.32% | $4.82M | $7.08B | 470.02% | 58 Neutral | |
| United Therapeutics | 3.53% | $3.94M | $23.34B | 68.76% | 79 Outperform | |
| Axsome Therapeutics | 3.16% | $3.52M | $11.96B | 107.60% | 57 Neutral | |
| Tenet Healthcare | 2.97% | $3.31M | $13.96B | -5.48% | 74 Outperform | |
| Tango Therapeutics | 2.85% | $3.18M | $2.92B | 374.65% | 59 Neutral | |
| SELLAS Life Sciences Group | 2.67% | $2.98M | $1.53B | 411.18% | 43 Neutral | |
| HCA Healthcare | 2.54% | $2.84M | $82.55B | -3.18% | 70 Neutral | |
| BrightSpring Health Services, Inc. | 2.52% | $2.82M | $11.13B | 138.08% | 67 Neutral | |
| Ionis Pharmaceuticals | 2.52% | $2.82M | $12.31B | 111.05% | 61 Neutral |
PTH Technical Analysis
Negative
―
Price Trends
50.94
Negative
49.82
Negative
47.67
Positive
Market Momentum
-0.47
Positive
38.83
Neutral
22.04
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PTH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 50.95, equal to the 50-day MA of 50.94, and equal to the 200-day MA of 47.67, indicating a neutral trend. The MACD of -0.47 indicates Positive momentum. The RSI at 38.83 is Neutral, neither overbought nor oversold. The STOCH value of 22.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTH.
PTH Peer Comparison
Comparison Results
Performance Comparison
PTH
Invesco DWA Healthcare Momentum ETF
48.46
10.79
28.64%
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PSCH
Invesco S&P SmallCap Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents